+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Guillain-Barre Syndrome Therapeutics - Global Strategic Business Report 2026

  • PDF Icon

    Report

  • 148 Pages
  • November 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5309885
The global market for Guillain-Barre Syndrome Therapeutics was valued at US$683.2 Million in 2025 and is projected to reach US$952.3 Million by 2032, growing at a CAGR of 4.9% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Guillain-Barré Syndrome (GBS) Therapeutics Market - Key Trends & Drivers Summarized

How Are Therapeutic Advances Impacting GBS Treatment?

Guillain-Barré Syndrome (GBS) therapeutics are advancing as medical research focuses on treatments that improve outcomes and reduce recovery times. GBS, a rare autoimmune disorder affecting the peripheral nervous system, typically requires intensive management, including immunoglobulin therapy (IVIG) and plasmapheresis, to reduce immune system attacks on nerves. New therapies are emerging to support nerve regeneration and reduce long-term disability in GBS patients, offering promising avenues for improved patient outcomes. These advances are particularly valuable as GBS often requires hospitalization and intensive care, which can be resource-intensive and costly.

Why Is Early Diagnosis Crucial for Effective GBS Management?

Early diagnosis is critical in GBS treatment, as timely intervention can significantly improve prognosis. With rapid diagnostic advancements, healthcare providers are increasingly able to recognize GBS symptoms sooner, initiating treatments that limit nerve damage and promote faster recovery. In many cases, immunoglobulin therapy and plasmapheresis are most effective when administered early, reducing the severity of symptoms and lowering the likelihood of long-term complications. This focus on early diagnosis and intervention is essential in managing GBS and highlights the importance of accessible diagnostic tools in improving patient outcomes.

How Are Patient-Centric Innovations Improving GBS Treatment Experience?

Patient-centric innovations, such as home-based IVIG administration and telemedicine consultations, are enhancing the treatment experience for GBS patients. These approaches allow for a more convenient and comfortable therapeutic journey, reducing hospital visits and facilitating early intervention. Telemedicine provides a valuable resource for GBS patients in remote or underserved areas, offering timely access to specialists and facilitating ongoing care. As healthcare systems prioritize patient-centered care, these innovations are supporting more effective and accessible treatment solutions for GBS patients, particularly in managing recovery outside traditional hospital settings.

What Drives the Growth of the GBS Therapeutics Market?

The growth in the GBS therapeutics market is driven by increased therapeutic advancements, the emphasis on early diagnosis, and patient-centric treatment innovations. Advances in treatments, including nerve regeneration therapies, are improving patient recovery outcomes and addressing long-term needs. Enhanced diagnostic tools are enabling earlier identification of GBS, supporting timely and effective intervention. Additionally, patient-centered innovations, such as home-based care options and telemedicine, are expanding treatment accessibility and improving patient experience. Together, these factors are driving the growth of the GBS therapeutics market as it adapts to evolving healthcare demands and therapeutic advancements.

Report Scope

The report analyzes the Guillain-Barre Syndrome Therapeutics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Other Therapeutics); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Intravenous Immunoglobulin segment, which is expected to reach US$542.4 Million by 2032 with a CAGR of a 5.3%. The Plasma Exchange segment is also set to grow at 4.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $199.9 Million in 2025, and China, forecasted to grow at an impressive 4.7% CAGR to reach $170.1 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Guillain-Barre Syndrome Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Guillain-Barre Syndrome Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Guillain-Barre Syndrome Therapeutics Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Akari Therapeutics Plc, Annexon Biosciences, Biotest AG, China Biologic Products, Inc., CSL Behring, LLC and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Guillain-Barre Syndrome Therapeutics market report include:

  • Akari Therapeutics Plc
  • Annexon Biosciences
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Behring, LLC
  • Grifols SA
  • Kedrion SpA
  • Nihon Pharmaceutical Co., Ltd.
  • Octapharma AG
  • Shire PLC

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Guillain-Barre Syndrome Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Guillain-Barre Syndrome Driving Treatment Demand
  • Advancements in Immunotherapy for Guillain-Barre Syndrome
  • Growth in Use of Intravenous Immunoglobulin (IVIG) Therapy
  • Increasing Focus on Early Diagnosis and Prompt Treatment Solutions
  • Expansion of Physical Therapy for Long-Term Recovery
  • Rising Adoption of Plasma Exchange as a Standard Treatment
  • Development of Novel Therapies Targeting Autoimmune Mechanisms
  • Growth in Research for Faster and More Effective Treatment Options
  • Higher Demand for Rehabilitation Services Supporting Recovery
  • Increased Investment in R&D for Neuromuscular Disorder Treatments
  • Expansion of Telemedicine Supporting Guillain-Barre Treatment Accessibility
  • Growth in Government Funding for Autoimmune Disorder Research
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Guillain-Barre Syndrome Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Guillain-Barre Syndrome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Intravenous Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Plasma Exchange by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Plasma Exchange by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Plasma Exchange by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 24: USA Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: USA 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 26: USA Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 27: USA Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: USA 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 30: Canada Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: Canada 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 32: Canada Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 33: Canada Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: Canada 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
JAPAN
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 36: Japan Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: Japan 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 38: Japan Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 39: Japan Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: Japan 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
CHINA
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 42: China Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: China 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 44: China Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 45: China Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: China 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
EUROPE
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 48: Europe Historic Review for Guillain-Barre Syndrome Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 49: Europe 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 50: Europe Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 51: Europe Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 52: Europe 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 53: Europe Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 54: Europe Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 55: Europe 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
FRANCE
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 57: France Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 58: France 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 59: France Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 60: France Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 61: France 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
GERMANY
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 63: Germany Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 64: Germany 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 65: Germany Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 66: Germany Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 67: Germany 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 69: Italy Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 70: Italy 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 71: Italy Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 72: Italy Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 73: Italy 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 75: UK Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 76: UK 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 77: UK Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 78: UK Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 79: UK 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 81: Rest of Europe Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 82: Rest of Europe 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 83: Rest of Europe Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 84: Rest of Europe Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 85: Rest of Europe 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
ASIA-PACIFIC
  • Guillain-Barre Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 88: Asia-Pacific 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 90: Asia-Pacific Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 91: Asia-Pacific 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
REST OF WORLD
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 93: Rest of World Historic Review for Guillain-Barre Syndrome Therapeutics by Therapeutics - Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 94: Rest of World 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for Intravenous Immunoglobulin, Plasma Exchange and Other Therapeutics for the Years 2020, 2026 & 2032
  • Table 95: Rest of World Recent Past, Current & Future Analysis for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 96: Rest of World Historic Review for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 97: Rest of World 13-Year Perspective for Guillain-Barre Syndrome Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2020, 2026 & 2032
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Akari Therapeutics Plc
  • Annexon Biosciences
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Behring, LLC
  • Grifols SA
  • Kedrion SpA
  • Nihon Pharmaceutical Co., Ltd.
  • Octapharma AG
  • Shire PLC

Table Information